期刊文献+

端粒酶逆转录酶和细胞增殖核抗原在喉鳞癌组织及细胞中的表达意义 被引量:1

Expression and clinical significance of TERT and PCNA in the tissue and cell lines of laryngeal squamaous cell carcinoma
原文传递
导出
摘要 目的研究端粒酶逆转录酶(TERT)和细胞增殖核抗原(PCNA)在喉鳞癌组织及细胞中的表达及其临床病理学意义。方法采用连续光谱扫描量子点免疫荧光组织化学方法检测喉鳞癌组织芯片中TERT和PCNA蛋白的表达情况;靶向抑制喉癌细胞株Hep-2的TERT,运用RT-PCR检测TERT和PCNA mRNA的表达情况。结果良恶性头颈部肿瘤中TERT和PCNA的表达差异有统计学意义(P〈0.01)。TERT在病理分级III级组中的阳性率明显高于Ⅰ-Ⅱ级组(P〈0.05),PCNA表达在病理分级Ⅲ级组中的阳性率显著高于Ⅰ-Ⅱ级组(P〈0.01),且TERT和PCNA的表达呈中度正相关性(r=0.577,P〈0.05);细胞实验中,靶向抑制TERT后,喉癌细胞株Hep-2增殖能力明显下降,TERT mRNA表达下调80%,PCNA mRNA表达同时下调70%。结论 TERT和PCNA与喉鳞癌的发生相关,且两者有协同作用,TERT影响肿瘤细胞增殖能力可能与PCNA表达变化有关。 Objective To investigate expression of TERT(telomerase reverse transcriptase) and PCNA(proliferating cell nuclear antigen) in the tissue and cell lines of laryngeal squamaous cell carcinoma,and to elucidate the clinical pathological significance.Methods A continuous mutiple-spectrums scan was applied to show expression of TERT and PCNA in tissue array.TERT and PCNA mRNA expression was measured in Hep-2 cells by RT-PCR test after siRNA inhibition.Results Expressions of TERT and PCNA were significantly different in benign and malignant head and neck cancers.Among the malignant,expression of TERT and PCNA were all higher in grade Ⅲ than grade Ⅰ-Ⅱ.Also,both expressions were moderately interrelated(r=0.577,P0.05).TERT mRNA level was decreased by 80% after siRNA inhibition,while the PCNA mRNA level was decreased by 70%.Conclusion TERT and PCNA are related to the development of laryngeal squamaous cell carcinoma.They are synergetic.It is possible that PCNA can exert an effect on TERT to modulate the proliferation of cancer cells.
出处 《山东大学耳鼻喉眼学报》 CAS 2011年第3期5-8,共4页 Journal of Otolaryngology and Ophthalmology of Shandong University
关键词 端粒酶逆转录酶 细胞增殖核抗原 量子点 RNA干扰 TERT PCNA Quantum dot RNA interference
  • 相关文献

参考文献9

  • 1Parkin D M, Pisani P, Ferlay J. Global cancer statistics[J]. CA Cancer J Clin, 1999, 49:33-64.
  • 2Parkin D M, Bray F, Ferlay J, et al. Global cancer statistics, 2002[J]. CA Cancer J Clin, 2005, 55:74-108.
  • 3Sampexiro Camarena F, Cano Serral G, Sampedro Santal6 F. Telomerase and telomere dynamics in ageing and canc- er: current status and future directions [J]. Clin Transl Oncol, 2007, 9:145-154.
  • 4Saretzki G. Telomerase inhibition as cancer therapy [ J ]. Cancer Letters, 2003, 194:209-219.
  • 5Czyzewska J, Guzifiska-Ustymowicz K, Pryczynicz A, et al. Immunohistochemical evaluation of Ki-67, PCNA and MCM2 proteins proliferation index (PI) in advanced gastric cancer[ J]. Folia Histochem Cytobiol, 2009, 47(2) : 289-296.
  • 6Chen C, Peng J, Xia H S, et al. Quantum dots-based immunofluorescence technology for the quantitative determi- nation of HER2 expression in breast cancer[J]. Biomaterials, 2009, 30:2912-2918.
  • 7Matsutani N, Yokozaki H, TahBra E, et al. Expression of MREllcomp lex (MRE11, RAD50, NBSI) and hrapl and its relation with telomere regulation, telomerase activity in human gastric carcinomas [ J ]. Pathobi ology, 2001,69:219-221.
  • 8Park J I, Venteicher A S, Hong J Y, et al. Telomerase modulates Wnt signalling by association with target gene chromatin [ J]. Nature, 2009, 460:66-72.
  • 9Takano H, Murasawa S, Asahara T. Functional and gene expression analysis of hTERT overexpressed endothelial cells [ J ]. Biologies, 2008, 2 (3) :547-554.

同被引文献44

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部